868551-76-2 Usage
Chemical structure
A complex organic compound with a fluoro-substituted benzyl group, a pyrrolopyridine core, and a carboxylic acid functional group.
Synonyms
BMS-911543
Target enzyme
Potent and selective inhibitor of Janus kinase 2 (JAK2)
JAK2 role
Plays a crucial role in signaling pathways involved in cell growth and proliferation.
Therapeutic applications
Studied for potential use in treating certain inflammatory and autoimmune diseases, as well as certain types of cancer.
Chemical mechanism
Inhibits JAK2 activity, potentially leading to reduced cell growth and proliferation in disease contexts.
Development
Promising candidate for further development as a pharmaceutical agent due to its unique chemical structure and mechanism of action.
Molecular weight
Approximately 409.39 g/mol (calculated from the molecular formula)
Solubility
Not explicitly mentioned, but as an organic compound, it is likely to be soluble in organic solvents such as DMSO or ethanol.
Check Digit Verification of cas no
The CAS Registry Mumber 868551-76-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,8,5,5 and 1 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 868551-76:
(8*8)+(7*6)+(6*8)+(5*5)+(4*5)+(3*1)+(2*7)+(1*6)=222
222 % 10 = 2
So 868551-76-2 is a valid CAS Registry Number.
868551-76-2Relevant academic research and scientific papers
Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. the impact of physicochemical properties on ADME and PK
Tanis, Steven P.,Plewe, Michael B.,Johnson, Ted W.,Butler, Scott L.,Dalvie, Deepak,Delisle, Dorothy,Dress, Klaus R.,Hu, Qiyue,Huang, Buwen,Kuehler, Jon E.,Kuki, Atsuo,Liu, Wen,Peng, Qinghai,Smith, Graham L.,Solowiej, Jim,Tran, Khanh T.,Wang, Hai,Yang, Anle,Yin, Chunfeng,Yu, Xiaoming,Zhang, Junhu,Zhu, Huichun
supporting information; experimental part, p. 7429 - 7434 (2011/02/26)
HIV-1 integrase is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the discovery of azaindole hydroxamic acids that
INHIBITORS OF THE HIV INTEGRASE ENZYME
-
Page/Page column 142-143, (2008/06/13)
The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
